Skip to main content
DFTX logo

DFTX · Definium Therapeutics, Inc. · Investor Relations

Track DFTX — free
$29.12 -0.26 (-0.88%) At close · Nov 18 Play latest call Q3 2026 earnings call transcript
Market Cap
$3.99B
Shares
136.90M
Volume · Nov 18 1.92M Avg daily vol (3M) 1.96M

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Upcoming events

Date Event Type
2026-12-01 20:50 UTC 9th Annual Evercore Healthcare Conference Conference
2026-12-02 21:00 UTC Piper Sandler 38th Annual Healthcare Conference Conference

Recent news

Date Headline
2026-11-04 Definium Therapeutics Presents Topline Phase 3 Data for DT120 ODT in Generalized Anxiety Disorder and Major Depressive Disorder at 2026 NEI Fall Congress
2026-11-03 Definium Therapeutics to Participate at Upcoming Investor Conferences
2026-10-29 Definium Therapeutics to Report Third Quarter 2026 Financial Results on November 9, 2026
2026-10-26 Definium Therapeutics Announces New Employee Inducement Grants
2026-10-13 Definium Therapeutics Announces New Employee Inducement Grants
2026-09-28 Definium Therapeutics Announces New Employee Inducement Grants
2026-09-14 Definium Therapeutics Announces Positive Topline Results from Phase 3 Panorama Study of DT120 ODT in Generalized Anxiety Disorder
2026-09-08 Definium Therapeutics Receives Breakthrough Therapy Designation for DT120 (lysergide) Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD) Following Positive Phase 3 Results
2026-08-12 Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of DT120 ODT in Generalized Anxiety Disorder
2026-08-06 Definium Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
2026-06-24 Definium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering
2026-06-24 Definium Therapeutics, Inc. Announces Proposed Public Offering
2026-06-22 Definium Therapeutics Announces Positive Topline Results from Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder
2026-05-12 Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder
2026-05-07 Definium Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
2026-04-22 Definium Therapeutics Highlights DT120 ODT (Lysergide Tartrate) Clinical Advancements and Commercial Strategy at Investor and Analyst Day
2026-02-26 Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates
2026-01-12 MindMed Rebrands to Definium Therapeutics, Advancing a Leading Late-Stage Psychiatry Pipeline with Three Phase 3 Readouts Expected in 2026
2025-11-06 MindMed Reports Q3 2025 Financial Results and Business Updates

Past events

Source: https://ir.definiumtx.com/

Key facts CIK 1813814 CUSIP 24477V105 13F (30d) 343 filings 335 filers Visit website Investor relations